Featured Research

from universities, journals, and other organizations

A Brain Chemical That Battles Despair

Date:
July 20, 2007
Source:
Cell Press
Summary:
Researchers have identified a gene-regulating protein in the brains of mice that triggers the animals' ability to cope with the "behavioral despair" caused by inescapable stress.

Researchers have identified a gene-regulating protein in the brains of mice that triggers the animals' ability to cope with the "behavioral despair" caused by inescapable stress. They said their studies have yielded an animal model of resilience that they will use to explore how antidepressants work on the brain circuitry involved in such stress response.

Led by Eric Nestler, the researchers published their findings in the July 19, 2007, issue of the journal Neuron, published by Cell Press.

In earlier studies, Nestler and his colleagues showed that exposure to repeated stress caused an increase in a protein called ∆FosB in the brain. This protein is a "transcription factor," a regulatory protein that controls the activity of multiple target genes.

In the new experiments, they sought to explore the role of ∆FosB in regulating adaptation to stress. Their approach involved first exposing mice to random shocks from which the animals could not escape. Such repeated exposure to inescapable stress tends to increase the lag time for mice to escape subsequent shocks, when they are given the chance to escape. Measuring this lag time, or the complete failure to escape, gave the researchers a measure of "behavioral despair." This experimental approach has long been used as an animal model of human "affective disorders" such as depression, posttraumatic stress disorder, and bipolar disorder. As in humans with such disorders, this behavioral despair in mice responds to antidepressants.

Nestler and colleagues discovered that the mice that showed the smallest lag in escape times also had higher levels of ∆FosB in a brain region involved in processing of pain signals and defensive responses. In contrast, animals with either longer escape lag times or failure to escape showed lower ∆FosB levels.

What's more, when the researchers introduced higher levels of the gene for ∆FosB into mice, they found it reduced the level of behavioral despair as reflected in their readiness to escape shocks.

The researchers also established that increased ∆FosB levels in the mice decreased the activity of the gene for a protein called "substance P¡" known to regulate processes such as mood, pain sensitivity, anxiety, and stress

"Our present results provide a fundamentally novel and testable model for the mechanisms of resilience," concluded the researchers. "Our future studies will test the hypothesis that antidepressant treatments may enhance resilience by stimulating these same adaptive processes which occur spontaneously in some, but not all, of the individuals in a population exposed to chronic stress," they wrote.

The researchers include Olivier Berton, Herbert E. Covington 3rd, Nadia M. Tsankova, Tiffany L. Carle, Paula Ulery, Akshay Bhonsle, Vaishnav Krishnan, Shari Birnbaum, and Eric J. Nestler of The University of Texas Southwestern Medical Center, Dallas; Michel Barrot of European Neuroscience Institute of Strasbourg and Unit Mixte de Recherche 7519, Centre National de la Recherche Scientifique/Universit Louis Pasteur, Strasbourg; Karl Ebner, Georg M. Singewald, and Nicolas Singewald of University of Innsbruck, Innsbruck; Rachael L. Neve of Harvard Medical School, McLean Hospital, Belmont.

This work was supported by grants from the National Institute of Mental Health, the National Alliance for Research on Schizophrenia and Depression, and la Fondation pour la Recherche Medicale.

Berton et al.: "Induction of ¦ÄFosB in the Periaqueductal Gray by Stress Promotes Active Coping Responses." Publishing in Neuron 55, 289¨C300, July 19, 2007. DOI 10.1016/j.neuron.2007.06.033. http://www.neuron.org.


Story Source:

The above story is based on materials provided by Cell Press. Note: Materials may be edited for content and length.


Cite This Page:

Cell Press. "A Brain Chemical That Battles Despair." ScienceDaily. ScienceDaily, 20 July 2007. <www.sciencedaily.com/releases/2007/07/070718140758.htm>.
Cell Press. (2007, July 20). A Brain Chemical That Battles Despair. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2007/07/070718140758.htm
Cell Press. "A Brain Chemical That Battles Despair." ScienceDaily. www.sciencedaily.com/releases/2007/07/070718140758.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins